Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care – – Statistically significant results demonstrated in all pre-specified hierarchical secondary endpoints… Read More
SAN DIEGO, Dec. 3, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that Mr…. Read More
SEATTLE, Nov. 26, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at… Read More
Newly-Diagnosed Patients Showing Promising Progression-Free Survival Compared to TMZ Historical Data Recurrent Patients Showing Promising Overall Survival Compared to Lomustine Historical Data SAN DIEGO, Nov. 25, 2019 /PRNewswire/ — DelMar Pharmaceuticals,… Read More
SAN DIEGO and VANCOUVER, British Columbia, Nov. 20, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, announced today that it has dosed the first patient… Read More
